Affordable Access

deepdyve-link
Publisher Website

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil).

Authors
  • Coleman, D Jackson1
  • Lee, Winston1
  • Daly, Suzanne1
  • Breazzano, Mark P1
  • Sparrow, Janet1
  • Tsang, Stephen H1, 2
  • 1 Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA.
  • 2 Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia Stem Cell Initiative, Departments of Ophthalmology, Pathology & Cell Biology, Institute of Human Nutrition, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA.
Type
Published Article
Journal
American journal of ophthalmology case reports
Publication Date
Mar 01, 2021
Volume
21
Pages
100998–100998
Identifiers
DOI: 10.1016/j.ajoc.2020.100998
PMID: 33364520
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Examine the use of systemic phosphodiesterase inhibition (sildenafil) to clear central serous chorioretinopathy (CSCR). In a long-standing CSCR patient, sildenafil produced a rapid resolution. When discontinued (dechallenge) the CSCR returned. When rechallenged, the CSCR again rapidly disappeared and did not recur in 5 months of continued therapy. AND IMPORTANCE: Systemic sildenafil can cause rapid clearance of CSCR and can augment or replace other treatments. © 2020 Published by Elsevier Inc.

Report this publication

Statistics

Seen <100 times